Aurinia Pharmaceuticals Inc. (AUPH): Shareholders' Equity
$581.33M
As of 2025-12-31
$614.86M
As of 2026-06-30
+12.8%
3-year compound annual growth
+7.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $581.33M | +54.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $377.48M | -0.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $377.95M | -6.8% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $405.44M | -15.4% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $479.09M | +17.5% | 2024-02-15, Balance as of period end |
| 2020-12-31 | $407.75M | +36.6% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $298.60M | +120.0% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $135.72M | n/a | 2021-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $581.33M | +54.0% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $658.86M | +69.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $604.52M | +4.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $715.24M | +38.1% |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗